PubMed:32178765 / 2546-2739 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PubMed/sourceid/32178765","sourcedb":"PubMed","sourceid":"32178765","source_url":"https://www.ncbi.nlm.nih.gov/pubmed/32178765","text":"Serious adverse events up to week 24 occurred in no patients receiving guselkumab every 4 weeks, four (3%) patients receiving guselkumab every 8 weeks, and five (4%) patients receiving placebo.","tracks":[{"project":"Inflammaging","denotations":[{"id":"T17","span":{"begin":0,"end":193},"obj":"Sentence"},{"id":"T17","span":{"begin":0,"end":193},"obj":"Sentence"}],"attributes":[{"subj":"T17","pred":"source","obj":"Inflammaging"},{"subj":"T17","pred":"source","obj":"Inflammaging"}]},{"project":"yaoziqian_800_3","denotations":[{"id":"T17","span":{"begin":71,"end":81},"obj":"CI"},{"id":"T18","span":{"begin":126,"end":136},"obj":"CI"},{"id":"T19","span":{"begin":185,"end":192},"obj":"CI"}],"attributes":[{"subj":"T17","pred":"source","obj":"yaoziqian_800_3"},{"subj":"T18","pred":"source","obj":"yaoziqian_800_3"},{"subj":"T19","pred":"source","obj":"yaoziqian_800_3"}]},{"project":"Zierdiyeerkenaili_800_3","denotations":[{"id":"T15","span":{"begin":71,"end":81},"obj":"CI"},{"id":"T16","span":{"begin":126,"end":136},"obj":"CI"},{"id":"T24","span":{"begin":185,"end":192},"obj":"CI"}],"attributes":[{"subj":"T15","pred":"source","obj":"Zierdiyeerkenaili_800_3"},{"subj":"T16","pred":"source","obj":"Zierdiyeerkenaili_800_3"},{"subj":"T24","pred":"source","obj":"Zierdiyeerkenaili_800_3"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"Inflammaging","color":"#ecd393","default":true},{"id":"yaoziqian_800_3","color":"#b993ec"},{"id":"Zierdiyeerkenaili_800_3","color":"#93ec9f"}]}]}}